MTOR and plasma cell myeloma: However, therapeutic attempts to interfere with the mTOR/PI3K/AKT pathway using mTORC1 inhibitors (e.g., rapalogs) demonstrated low efficacy against myeloma because of induction of negative feedback circuits increasing mTORC2 activity (30, 31).